文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

接受姑息性胸部放疗的非小细胞肺癌患者血清细胞因子谱与代谢肿瘤负荷

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy.
PubMed 文献 · Adv Radiat Oncol · 2018-02-13

这项2期临床试验纳入45例晚期非小细胞肺癌患者,随机接受单纯分次胸部放疗或联合同期表皮生长因子受体抑制剂,在4个时间点检测48种细胞因子和9种基质金属蛋白酶,部分患者行18F-FDG PET/CT评估代谢肿瘤负荷。结果显示SUVmax从基线至治疗中期至治疗后下降(P = .018),CCL23、CCL24、CX3CL1和IL-8(CXCL8)与SUVmax、代谢肿瘤体积和总病灶糖酵解显著相关。

要点

  • 45例晚期NSCLC患者随机接受单纯胸部放疗或联合同期EGFR抑制剂。
  • SUVmax从基线至治疗中期至治疗后下降(P = .018)。
  • CCL23、CCL24、CX3CL1和IL-8与SUVmax、MTV和TLG显著相关。

核心结论

  • 在接受姑息性胸部放疗的晚期非小细胞肺癌患者中,血清细胞因子水平存在变化并与代谢肿瘤负荷相关。

研究设计与样本

  • 2期临床试验纳入45例晚期非小细胞肺癌患者,随机分为单纯分次胸部放疗组或联合同期表皮生长因子受体抑制剂组。
  • 于治疗前、治疗中期、治疗结束时和治疗开始后6至8周共4个时间点采血,用多重免疫分析检测48种细胞因子和9种基质金属蛋白酶。
  • 部分患者在放疗前、中、后行18F-FDG PET/CT检查,计算原发肺肿瘤SUVmax、全身代谢肿瘤体积和总病灶糖酵解。

主要发现

  • SUVmax从基线至治疗中期至治疗后18F-FDG PET/CT下降(P = .018)。
  • CCL23、CCL24、CX3CL1和IL-8(CXCL8)的血清水平在放疗前、中、后均与SUVmax、代谢肿瘤体积和总病灶糖酵解显著相关。
  • CXCL2(P = .030)和CXCL6(P = .010)在治疗开始后下降,并在各采样时间点间变化显著。
  • 治疗第2周时,CCL15(P = .031)、CXCL2(P = .028)和IL-6(P = .007)的血清浓度与照射体积呈正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy effectively kills cancer cells and elicits local effects in the irradiated tissue. The aim of this study was to investigate the kinetics of cytokines in the serum of patients with lung cancer undergoing radiation therapy and to identify associations with metabolic tumor burden as determined by 2-deoxy-2-fluoro-D-glucose (18F-FDG) positron emission tomography (PET). METHODS AND MATERIALS: Forty-five patients with advanced non-small cell lung cancer were included in a phase 2 clinical trial and randomized between fractionated thoracic radiation therapy alone or concurrent with an epidermal growth factor receptor inhibitor. Blood was sampled at 4 different time points: prior to treatment, midtherapy, at the end of therapy, and 6 to 8 weeks after the start of treatment. The serum concentrations of 48 cytokines and 9 matrix metalloproteinases were measured with multiplex immunoassays. A subset of patients was examined by 18F-FDG PET/computed tomography before, during, and after radiation therapy. The maximum standardized uptake values (SUVmax) of the primary lung tumor, whole-body metabolic tumor volume, and total lesion glycolysis were calculated, and correlations between the PET parameters and cytokines were investigated. RESULTS: The SUVmax decreased from baseline through midtherapy to posttherapy 18F-FDG PET/computed tomography (P = .018). The serum levels of C-C motif chemokine ligand (CCL) 23, CCL24, C-X3-C motif chemokine ligand 1, and interleukin-8 (C-X-C motif ligand [CXCL]8) were significantly correlated to SUVmax, metabolic tumor volume, and total lesion glycolysis before, during, and after radiation therapy. CXCL2 (P = .030) and CXCL6 (P = .010) decreased after the start of therapy and changed significantly across the sample time points. Serum concentrations of CCL15 (P = .031), CXCL2 (P = .028), and interleukin-6 (P = .007) were positively correlated to the irradiated volume during the second week of treatment. CONCLUSIONS: Cytokine serum levels vary and correlate with metabolic tumor burden in patients with advanced non-small cell lung cancer undergoing palliative thoracic radiation therapy.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Eide HA, Knudtsen IS, Sandhu V, et al. Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy. Adv Radiat Oncol. 2018. PMID: 29904737. doi:10.1016/j.adro.2017.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。